Symbols / BBLG
BBLG Chart
About
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's lead medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company's NELL-1 platform technology used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.08M |
| Enterprise Value | -4.00M | Income | -3.95M | Sales | — |
| Book/sh | 3.35 | Cash/sh | 3.37 | Dividend Yield | — |
| Payout | 0.00% | Employees | 2 | IPO | — |
| P/E | — | Forward P/E | -0.85 | PEG | — |
| P/S | — | P/B | 0.35 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 18.10 |
| Current Ratio | 19.00 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.40 | EPS next Y | -1.36 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 16:00 | ROA | -48.68% |
| ROE | -80.46% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.80M |
| Shs Float | 1.79M | Short Float | 2.53% | Short Ratio | 1.17 |
| Short Interest | — | 52W High | 6.75 | 52W Low | 1.11 |
| Beta | 0.41 | Avg Volume | 312.33K | Volume | 5.83K |
| Target Price | $22.25 | Recom | None | Prev Close | $1.14 |
| Price | $1.16 | Change | 1.75% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$22.25
Mean price target
2. Current target
$1.16
Latest analyst target
3. DCF / Fair value
$-19.71
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.16
Low
$22.25
High
$22.25
Mean
$22.25
- Bone-healing treatment in development now lasts 2 years on the shelf in tests - Stock Titan ue, 23 Dec 2025 08
- BBLG Stocks on the Verge: How Will They Perform? - StocksToTrade ue, 23 Dec 2025 08
- Bone Biologics Prices $5 Mln Public Offering With Warrants At $4 Per Share - Nasdaq Fri, 27 Jun 2025 07
- Bone Biologics stock rises after extending product shelf life - Investing.com ue, 23 Dec 2025 08
- Game-Changing Bone Regeneration Patent: Bone Biologics Advances New Spine Fusion Treatment - Stock Titan Fri, 27 Jun 2025 07
- Bone Biologics Announces 1-for-6 Reverse Stock Split - citybiz Fri, 06 Jun 2025 07
- Bone Biologics Announces Pricing of $5.0 Million Public Offering - Yahoo Finance Fri, 27 Jun 2025 07
- Bone Biologics CEO issues letter to stockholders highlighting company update and outlook - marketscreener.com hu, 04 Sep 2025 07
- $5M Funding Secured: Bone Biologics Advances Revolutionary Spine Fusion Treatment with Extended Shelf Life - Stock Titan hu, 04 Sep 2025 07
- Bone Biologics expects to complete enrollment in NB1 clinical trial - Investing.com hu, 04 Sep 2025 07
- Bone Biologics (BBLG) - Zacks Investment Research Sat, 16 Oct 2021 03
- Spine Fusion Developer Bone Biologics to Showcase at Major H.C. Wainwright Investment Conference - Stock Titan Wed, 03 Sep 2025 07
- Why Is OncoSec Medical (ONCS) Stock Down 48% Today? - InvestorPlace hu, 15 Jun 2023 07
- BBLG Stock Price, News & Analysis - Stock Titan Fri, 25 Apr 2025 02
- Bone Biologics Prices $5,100,000 Underwritten Public Offering - citybiz Fri, 07 Oct 2022 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -4.27M | -9.91M | -6.58M | -1.10M |
| TotalUnusualItems | 51.08K | 477.70K | 2.91M | 297.50K |
| TotalUnusualItemsExcludingGoodwill | 51.08K | 477.70K | 2.91M | 297.50K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -4.11M | -8.95M | -1.48M | -1.61M |
| ReconciledCostOfRevenue | 0.00 | 0.00 | ||
| EBITDA | -4.22M | -9.43M | -3.67M | -805.58K |
| EBIT | -4.22M | -9.43M | -3.67M | -805.58K |
| NetInterestIncome | 55.66K | 1.87K | -731.71K | -805.11K |
| InterestExpense | 0.00 | 805.11K | ||
| InterestIncome | 55.66K | 1.87K | 0.00 | |
| NormalizedIncome | -4.16M | -9.43M | -4.40M | -1.91M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -4.11M | -8.95M | -1.48M | -1.61M |
| TotalExpenses | 4.22M | 9.43M | 3.67M | 1.10M |
| TotalOperatingIncomeAsReported | -4.22M | -9.43M | -3.67M | -1.10M |
| DilutedAverageShares | 252.87K | 43.86K | 7.94K | 3.15K |
| BasicAverageShares | 252.87K | 43.86K | 7.94K | 3.15K |
| DilutedEPS | -28.98 | -204.06 | -186.90 | -504.00 |
| BasicEPS | -28.98 | -204.06 | -186.90 | -504.00 |
| DilutedNIAvailtoComStockholders | -7.32M | -8.95M | -1.48M | -1.61M |
| NetIncomeCommonStockholders | -7.32M | -8.95M | -1.48M | -1.61M |
| OtherunderPreferredStockDividend | 3.21M | 0.00 | ||
| NetIncome | -4.11M | -8.95M | -1.48M | -1.61M |
| NetIncomeIncludingNoncontrollingInterests | -4.11M | -8.95M | -1.48M | -1.61M |
| NetIncomeContinuousOperations | -4.11M | -8.95M | -1.48M | -1.61M |
| TaxProvision | 1.60K | |||
| PretaxIncome | -4.11M | -8.95M | -1.48M | -1.61M |
| OtherIncomeExpense | 51.08K | 477.70K | 2.91M | 297.50K |
| SpecialIncomeCharges | 0.00 | -414.99K | 0.00 | 297.50K |
| OtherSpecialCharges | 414.99K | -297.50K | ||
| GainOnSaleOfSecurity | 51.08K | 892.69K | 2.91M | |
| NetNonOperatingInterestIncomeExpense | 55.66K | 1.87K | -731.71K | -805.11K |
| TotalOtherFinanceCost | 731.71K | |||
| InterestExpenseNonOperating | 0.00 | 805.11K | ||
| InterestIncomeNonOperating | 55.66K | 1.87K | 0.00 | |
| OperatingIncome | -4.22M | -9.43M | -3.67M | -1.10M |
| OperatingExpense | 4.22M | 9.43M | 3.67M | 1.10M |
| ResearchAndDevelopment | 2.13M | 6.91M | 1.58M | 82.04K |
| SellingGeneralAndAdministration | 2.09M | 2.52M | 2.09M | 1.02M |
| GeneralAndAdministrativeExpense | 2.09M | 2.52M | 2.09M | 1.02M |
| OtherGandA | 2.09M | 2.52M | 2.09M | 1.02M |
| GrossProfit | 0.00 | 0.00 | ||
| CostOfRevenue | 0.00 | 0.00 | ||
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 492.33K | 89.04K | 10.63K | 7.19K |
| ShareIssued | 492.33K | 89.04K | 10.63K | 7.19K |
| TangibleBookValue | 3.48M | 2.91M | 5.95M | 6.58M |
| InvestedCapital | 3.48M | 2.91M | 5.95M | 6.58M |
| WorkingCapital | 3.48M | 2.91M | 5.95M | 6.58M |
| NetTangibleAssets | 3.48M | 2.91M | 5.95M | 6.58M |
| CommonStockEquity | 3.48M | 2.91M | 5.95M | 6.58M |
| TotalCapitalization | 3.48M | 2.91M | 5.95M | 6.58M |
| TotalEquityGrossMinorityInterest | 3.48M | 2.91M | 5.95M | 6.58M |
| StockholdersEquity | 3.48M | 2.91M | 5.95M | 6.58M |
| RetainedEarnings | -85.02M | -80.91M | -71.96M | -70.48M |
| AdditionalPaidInCapital | 88.50M | 83.81M | 77.91M | 77.04M |
| CapitalStock | 2.95K | 534.00 | 64.00 | 10.35K |
| CommonStock | 2.95K | 534.00 | 64.00 | 10.35K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 377.71K | 831.40K | 2.55M | 99.91K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 377.71K | 831.40K | 2.55M | 99.91K |
| OtherCurrentLiabilities | 4.67K | 55.75K | 1.66M | |
| CurrentDeferredLiabilities | 0.00 | 0.00 | 783.67K | 0.00 |
| CurrentDeferredRevenue | 0.00 | 0.00 | 783.67K | |
| LineOfCredit | 0.00 | |||
| CurrentNotesPayable | 0.00 | |||
| PayablesAndAccruedExpenses | 373.04K | 775.65K | 104.79K | 99.91K |
| CurrentAccruedExpenses | 0.00 | 414.99K | 0.00 | |
| InterestPayable | 0.00 | |||
| Payables | 373.04K | 360.66K | 104.79K | 99.91K |
| AccountsPayable | 373.04K | 360.66K | 104.79K | 99.91K |
| TotalAssets | 3.86M | 3.74M | 8.50M | 6.68M |
| TotalNonCurrentAssets | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 3.86M | 3.74M | 8.50M | 6.68M |
| PrepaidAssets | 536.24K | 711.19K | 956.92K | 0.00 |
| Receivables | 328.84K | 579.91K | ||
| OtherReceivables | 328.84K | 579.91K | ||
| CashCashEquivalentsAndShortTermInvestments | 3.33M | 3.03M | 7.54M | 6.68M |
| CashAndCashEquivalents | 3.33M | 3.03M | 7.54M | 6.68M |
| CashFinancial | 3.33M | 3.03M | 7.54M | 6.68M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -4.12M | -9.56M | -3.57M | -1.23M |
| RepaymentOfDebt | 0.00 | -10.61K | ||
| IssuanceOfDebt | 0.00 | 1.06M | ||
| IssuanceOfCapitalStock | 2.62M | 5.04M | 4.43M | 6.86M |
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | 12.06K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 3.33M | 3.03M | 7.54M | 6.68M |
| BeginningCashPosition | 3.03M | 7.54M | 6.68M | 0.00 |
| ChangesInCash | 298.56K | -4.51M | 862.95K | 6.68M |
| FinancingCashFlow | 4.42M | 5.04M | 4.43M | 7.90M |
| CashFlowFromContinuingFinancingActivities | 4.42M | 5.04M | 4.43M | 7.90M |
| ProceedsFromStockOptionExercised | 1.81M | 0.00 | ||
| NetCommonStockIssuance | 2.62M | 5.04M | 4.43M | 6.86M |
| CommonStockIssuance | 2.62M | 5.04M | 4.43M | 6.86M |
| NetIssuancePaymentsOfDebt | 0.00 | 1.05M | ||
| NetShortTermDebtIssuance | 0.00 | 1.05M | ||
| ShortTermDebtPayments | 0.00 | -10.61K | ||
| ShortTermDebtIssuance | 0.00 | 1.06M | ||
| OperatingCashFlow | -4.12M | -9.56M | -3.57M | -1.23M |
| CashFlowFromContinuingOperatingActivities | -4.12M | -9.56M | -3.57M | -1.23M |
| ChangeInWorkingCapital | -150.25K | 132.92K | -168.37K | -320.49K |
| ChangeInOtherWorkingCapital | -783.67K | 783.67K | 45.00K | |
| ChangeInPayablesAndAccruedExpense | -325.21K | 670.87K | 4.88K | -365.49K |
| ChangeInAccruedExpense | -414.99K | 414.99K | 0.00 | |
| ChangeInPayable | 89.78K | 255.88K | 4.88K | |
| ChangeInAccountPayable | 89.78K | 255.88K | 4.88K | |
| ChangeInPrepaidAssets | 174.96K | 245.73K | -956.92K | 0.00 |
| OtherNonCashItems | 731.71K | 495.55K | ||
| StockBasedCompensation | 188.82K | 152.60K | 266.63K | 207.03K |
| OperatingGainsLosses | -51.08K | -892.69K | -2.91M | |
| GainLossOnInvestmentSecurities | -51.08K | -892.69K | -2.91M | |
| NetIncomeFromContinuingOperations | -4.11M | -8.95M | -1.48M | -1.61M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BBLG
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|